Supplementary Table 1. Multivariate analyses for overall survival after brain metastasis and brain metastasis-specific survival after brain metastasis.
| Factor | OSBM | BMSS | ||
|---|---|---|---|---|
| Hazard ratio | p-value | Hazard ratio | p-value | |
| Treatment | 0.072 | 0.084 | ||
| FBT | Reference | Reference | ||
| Non-FBT | 0.66 (0.42-1.04) | 0.57 (0.31-1.08) | ||
| ER | 0.952 | |||
| Positive | Reference | NA | ||
| Negative | 0.96 (0.29-3.19) | |||
| PR | 0.001 | 0.002 | ||
| Positive | Reference | Reference | ||
| Negative | 0.37 (0.20-0.70) | 0.36 (0.19-0.69) | ||
| Histologic grade | NA | 0.116 | ||
| I, II | Reference | |||
| III | 0.82 (0.34-1.12) | |||
| Subtype | 0.453 | NA | ||
| TN | Reference | |||
| HR+HER2- | 0.80 (0.19-3.28) | 0.755 | ||
| HR+HER2+ | 1.11 (0.30-4.14) | 0.878 | ||
| HR-HER2+ | 0.66 (0.35-1.27) | 0.215 | ||
| No. of metastases in brain | 0.02 | 0.028 | ||
| Multiple (≥5) | Reference | Reference | ||
| Single | 0.43 (0.23-0.80) | 0.008 | 0.40 (0.18-0.90) | 0.026 |
| Oligometastasis (2-4) | 0.64 (0.40-1.02) | 0.06 | 0.45 (0.23-0.90) | 0.024 |
OSBM=overall survival after brain metastasis; BMSS=brain metastasis-specific survival; FBT=focal brain treatment; ER=estrogen receptor; NA=not associated; PR=progesterone receptor; TN=triple-negative; HR=hormone receptor; HER2=human epidermal growth factor receptor 2.